NFG
CODX

Next Financial Group’s Co-Diagnostics CODX Stock Holding History

Next Financial Group’s Portfolio CODX Stock Details CODX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$8K Sell
32
-73
-70% -$19.1K ﹤0.01% 2258
2021
Q3 		$31K Buy
+105
New +$30.6K ﹤0.01% 1619

Other funds holding CODX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
ARC
Advisor Resource Council Dallas, Texas $309M AUM 22.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Next Financial Group's CODX Position: Q4 2021 in Review

Next Financial Group reduced its Co-Diagnostics (CODX) stake by 70% in Q4 2021, selling an estimated $19.1K and leaving 32 shares worth $8K. The position accounts for ﹤0.01% of the portfolio, ranked #2258.

Next Financial Group first reported a position in CODX in Q3 2021 and has held it in 2 quarters since. The position peaked at $31K in Q3 2021. 77 funds tracked by Wall St. Rank hold CODX as of Q4 2021.

  • Next Financial Group held 32 shares of Co-Diagnostics worth $8K as of Q4 2021.
  • Next Financial Group sold 73 Co-Diagnostics shares in Q4 2021, an estimated $19.1K.
  • Co-Diagnostics made up ﹤0.01% of Next Financial Group's portfolio in Q4 2021, its #2258 holding.
  • Next Financial Group first reported a position in Co-Diagnostics in Q3 2021 and has held it in 2 quarters since.
  • Next Financial Group's Co-Diagnostics position peaked at $31K in Q3 2021.
  • 77 funds tracked by Wall St. Rank held Co-Diagnostics as of Q4 2021.

Based on Next Financial Group's 13F filing for Q4 2021, filed 15 Feb 2022.